ERBB3 and ovarian carcinoma: Recent studies suggest that erbB3 signaling also contributes to chemoresistance in ovarian cancer, as the chemotherapeutic drug doxorubicin upregulates erbB3 ligands to activate the erbB3/PI-3 K/Akt signaling in ovarian cancer cells [74].